Christopher Rhodes to Interleukin-6
This is a "connection" page, showing publications Christopher Rhodes has written about Interleukin-6.
Connection Strength
0.515
-
Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension. Eur Respir J. 2024 Apr; 63(4).
Score: 0.220
-
Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension. Heart. 2011 Jul; 97(13):1054-60.
Score: 0.090
-
Circulating markers of inflammation and angiogenesis and clinical outcomes across subtypes of pulmonary arterial hypertension. J Heart Lung Transplant. 2023 02; 42(2):173-182.
Score: 0.050
-
Maternal and perinatal obesity induce bronchial obstruction and pulmonary hypertension via IL-6-FoxO1-axis in later life. Nat Commun. 2022 07 27; 13(1):4352.
Score: 0.049
-
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension. Eur Respir J. 2022 03; 59(3).
Score: 0.048
-
Association of synovial inflammation and inflammatory mediators with glenohumeral rotator cuff pathology. J Shoulder Elbow Surg. 2016 Jun; 25(6):989-97.
Score: 0.031
-
The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem. 2005 Feb 11; 280(6):4617-26.
Score: 0.014
-
Phosphoinositide 3 kinase mediates Toll-like receptor 4-induced activation of NF-kappa B in endothelial cells. Infect Immun. 2003 Aug; 71(8):4414-20.
Score: 0.013